Chapter 5. Development of Fourth Hurdle Policies Around the World

  1. Nick Freemantle1 and
  2. Suzanne Hill2
  1. Rod S Taylor,
  2. Mike F Drummond,
  3. Glen Salkeld and
  4. Sean D Sullivan

Published Online: 5 NOV 2007

DOI: 10.1002/9780470994719.ch5

Evaluating Pharmaceuticals for Health Policy and Reimbursement

Evaluating Pharmaceuticals for Health Policy and Reimbursement

How to Cite

Taylor, R. S., Drummond, M. F., Salkeld, G. and Sullivan, S. D. (2004) Development of Fourth Hurdle Policies Around the World, in Evaluating Pharmaceuticals for Health Policy and Reimbursement (eds N. Freemantle and S. Hill), Blackwell Science Ltd, Oxford, UK. doi: 10.1002/9780470994719.ch5

Editor Information

  1. 1

    Department of Primary Care and General Practice, University of Birmingham,Birmingham,UK

  2. 2

    Faculty of Health,University of Newcastle,Newcastle, Australia

Publication History

  1. Published Online: 5 NOV 2007
  2. Published Print: 1 AUG 2004

ISBN Information

Print ISBN: 9780727917843

Online ISBN: 9780470994719

SEARCH

Keywords:

  • fourth hurdle policies;
  • health care system;
  • pharmaceutical industry;
  • national institute for clinical excellence;
  • european countries

Summary

This chapter contains sections titled:

  • Introduction

  • Emergence of the fourth hurdle

  • Global development

  • Europe

  • USA

  • The rest of the world

  • Summary

  • Impact of the fourth hurdle

  • Quality of pharmacoeconomic evidence

  • Access to more cost-effective drugs?

  • Reduced drug costs?

  • The future

  • Harmonising fourth hurdle systems

  • Confidentiality and openness

  • Risk sharing models

  • Conclusion

  • References